查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088838

胃食道逆流症 (GERD) 治療市場：2026-2032 年全球市場預測（按療法、劑型、給藥途徑、藥物類型、藥物核准情況、疾病嚴重程度、分銷管道和最終用戶分類）

Gastroesophageal Reflux Disease Therapeutics Market by Treatment Type, Dosage Form, Route Of Administration, Medicine Type, Drug Status, Disease Severity, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，胃食道逆流症 (GERD) 治療市場將成長至 78.8 億美元，複合年成長率為 5.36%。

主要市場統計數據
基準年 2025 54.6億美元
預計年份：2026年 57.4億美元
預測年份 2032 78.8億美元
複合年成長率 (%) 5.36%

執行摘要：胃食道逆流症的治療

胃食道逆流症 (GERD) 藥物用於治療一種以胃內容物逆流為特徵的慢性復發性疾病。這種疾病會引起令人不適的灼熱、逆流、睡眠障礙、生活品質下降，以及糜爛性食道炎、消化性狹窄和巴瑞特氏食道症等併發症。雖然美國胃腸病學會 (ACG) 臨床試驗建議對無危險因子的典型病例進行質子幫浦阻斷劑(PPI) 的經驗性治療，但對於出現併發症、難治性病例或診斷不明的病例，內視鏡檢查和逆流監測仍然至關重要。

將重塑胃食道逆流症治療的變革性變化

胃食道逆流症（GERD）的治療模式正從單純的症狀緩解轉向精準診斷、黏膜修復、持續抑制胃酸分泌以及長期安全管理。美國食品藥物管理局（FDA）於2020年因擔心NDMA雜質而召回雷尼替丁製劑，這極大地改變了H2受體阻斷劑的使用方式，並促使人們更加關注藥物安全監測、雜質檢測和供應鏈品管。

人工智慧在胃食道逆流症治療的累積影響

人工智慧正開始影響胃食道逆流（GERD）治療的各個層面，從藥物研發和診斷到臨床試驗設計和真實世界數據。透過利用機器學習，我們可以分析內視鏡影像、電子健康記錄、症狀日記、pH電阻測量數據和處方模式，從而識別出症狀頑固、出現預警訊號、用藥依從性差或潛在藥物交互作用風險的患者。

關於胃食道逆流症治療的關鍵區域性見解

亞太地區擁有龐大的患者群體、不斷變化的都市區飲食習慣、日益普及的私人醫療保健以及成熟的抑酸藥物處方實踐，因此蘊藏著巨大的市場機會。尤其值得一提的是，日本在鉀離子競爭性抑酸藥物的臨床應用方面積累了豐富的經驗，並且多個國家正在擴大胃腸病學服務的覆蓋範圍。北美則憑藉其高診斷率、豐富的非處方藥和處方藥供應、完善的胃腸病學網路、FDA批准以及保險公司對差異化療法的嚴格審查，繼續保持著高階市場的地位。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協市場，儘管存在區域差異，但需求仍在成長。這主要得益於零售藥局的普及、醫院專科服務的可近性以及中產階級醫療保健支出的成長，儘管各國醫保報銷體系的成熟度有所不同。海灣合作理事會（GCC）地區代謝性疾病負擔沉重，保險體係不斷完善，且對三級醫療投入巨大，因此，在醫保報銷體系和處方藥目錄完善的地區，對成熟的質子幫浦抑制劑（PPI）和高階療法的需求均有所成長。

對首選 GERD 市場關鍵國家的洞察

美國憑藉其FDA核准途徑、從非處方藥到處方藥的廣泛通路、廣泛的消費者意識以及療效顯著且符合醫保報銷條件的差異化藥物的快速普及，引領著藥品商業化進程。加拿大強調實證報銷，而墨西哥和巴西作為大型市場，其藥品市場受COFEPRIS和ANVISA監管、學名藥滲透率以及進入私部門通路等因素的影響。英國、德國、法國、義大利和西班牙是成熟的歐洲市場，其NICE、AMNOG、HAS以及區域採購框架對藥品定價、處方和納入處方藥目錄均有影響。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化證據，而非漸進式定位。臨床計畫應證明其在治癒率、持續症狀控制、夜間症狀緩解、依從性提高、安全性以及對標準PPI療效不佳患者的價值方面具有優勢。應儘早累積真實世界證據，以支持與支付方的磋商、整合到治療路徑中以及符合臨床指南。

調查方法

本執行摘要是根據臨床指南、監管公告、同行評審文獻、公共衛生資料集、醫療政策資訊來源以及公開可用的治療藥物類別資訊的系統性回顧。主要參考文獻包括胃腸病學會的指導意見、美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 的監管資訊、國家醫保報銷框架以及來自權威公共衛生機構的流行病學數據。

結論

由於逆流症狀普遍存在、復發頻繁，且通常需要長期治療，胃食道逆流症 (GERD) 的治療仍然是一個重要且臨床上不可或缺的領域。雖然非專利抑制劑 (PPI) 仍然是治療的基石，但創新正在不斷拓展，例如 PCAB、最佳化製劑、數位監測以及針對難治性或併發症疾病的實證治療方案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：胃食道逆流症治療市場：依治療類型分類

  • 藥物治療
    • 質子幫浦阻斷劑（PPI）
    • H2受體拮抗劑
    • 制酸劑
    • 黏膜敷料
      • 硫糖鋁和黏膜敷料
      • 藻酸鹽/筏狀形成劑
  • 手術介入
  • 使用醫療設備的治療方法

第8章：胃食道逆流症治療市場：依劑型分類

  • 膠囊
  • 液體
  • 懸浮液
  • 藥片

第9章：胃食道逆流症治療市場：依給藥途徑分類

  • 口服
  • 注射藥物

第10章：胃食道逆流症治療市場：依藥物類型分類

  • 非處方藥
  • 處方

第11章：胃食道逆流症治療市場：依藥物核准情況

  • 品牌
  • 非專利的

第12章：胃食道逆流症治療市場：依疾病嚴重程度分類

  • 溫和的
  • 緩和
  • 嚴重

第13章：胃食道逆流症治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章：胃食道逆流症治療市場：依最終使用者分類

  • 居家醫療
  • 醫院
  • 專科診所

第15章：胃食道逆流症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章：胃食道逆流症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：胃食道逆流症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cadila Pharmaceuticals Ltd.
  • Camber Pharmaceuticals, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • Dr. Reddy's Laboratories Limited
  • Eisai Co., Ltd.
  • Elite Wealth Ltd.
  • Haleon plc
  • HK inno.N Co., Ltd.
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Onconic Therapeutics Inc.
  • Pfizer Inc.
  • Phathom Pharmaceuticals, Inc.
  • RaQualia Pharma Inc.
  • Reckitt Benckiser Group plc
  • Sandoz Group AG
  • Sanofi SA
  • Sebela Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Procter & Gamble Company
  • Viatris Inc.
Product Code: MRR-AD36CD897D13

The Gastroesophageal Reflux Disease Therapeutics Market is projected to grow by USD 7.88 billion at a CAGR of 5.36% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.46 billion
Estimated Year [2026] USD 5.74 billion
Forecast Year [2032] USD 7.88 billion
CAGR (%) 5.36%

Executive Summary: Gastroesophageal Reflux Disease Therapeutics

Gastroesophageal reflux disease therapeutics address a chronic, relapsing condition characterized by reflux of gastric contents that causes troublesome heartburn, regurgitation, sleep disruption, reduced quality of life, and complications such as erosive esophagitis, peptic stricture, and Barrett's esophagus. Clinical guidance from the American College of Gastroenterology supports an empiric proton pump inhibitor trial for typical symptoms without alarm features, while endoscopy and reflux monitoring remain central for complicated, refractory, or diagnostically uncertain cases.

The market is anchored by widely used proton pump inhibitors, H2-receptor antagonists, antacids, alginates, prokinetics in selected settings, and newer potassium-competitive acid blockers. Demand is reinforced by obesity, aging populations, dietary patterns, OTC availability, and growing recognition of non-erosive reflux disease, making GERD therapeutics a high-volume category across prescription and consumer health channels.

Transformative Shifts Reshaping GERD Treatment

The GERD therapeutics landscape is shifting from symptom suppression alone toward precision diagnosis, mucosal healing, durable acid control, and long-term safety management. The 2020 FDA request to remove ranitidine products because of NDMA impurity concerns reshaped H2 blocker use and increased attention to pharmacovigilance, impurity testing, and supply-chain quality.

Innovation is also changing competitive dynamics. Potassium-competitive acid blockers, including vonoprazan, provide rapid and sustained acid suppression and have gained regulatory traction in major markets. At the same time, payers continue to favor low-cost generic PPIs, creating a market where differentiated therapies must prove clinical value in erosive esophagitis healing, symptom relief, adherence, and outcomes in PPI-inadequate responders.

Cumulative Impact of Artificial Intelligence in GERD Therapeutics

Artificial intelligence is beginning to influence GERD therapeutics across discovery, diagnosis, trial design, and real-world evidence. Machine learning can analyze endoscopy images, electronic health records, symptom diaries, pH-impedance datasets, and prescription patterns to identify patients with refractory symptoms, alarm features, adherence gaps, or potential drug-drug interaction risks.

The cumulative impact is operational as much as scientific. AI-enabled pharmacovigilance can detect safety signals earlier, while predictive analytics can support patient segmentation for PPIs, H2 blockers, alginates, PCABs, or procedural referral. For manufacturers and healthcare stakeholders, AI can shorten evidence generation cycles by improving site selection, patient recruitment, real-world outcomes assessment, health economic modeling, and post-launch performance tracking.

Key Regional Insights Across GERD Therapeutics

Asia-Pacific is a high-volume opportunity because of large patient populations, urban dietary changes, growing private healthcare use, and established acid-suppression prescribing, with Japan offering early clinical experience in potassium-competitive acid blockers and several countries expanding access to gastroenterology services. North America remains a premium market driven by high diagnosis rates, OTC and prescription availability, strong gastroenterology networks, FDA approvals, and significant payer scrutiny of differentiated therapies.

Latin America relies heavily on generics and retail pharmacy access, while Brazil and Mexico provide scale through large urban populations, expanding specialty care, and rising use of structured regulatory pathways. Europe combines strong guideline adoption, generic cost containment, and centralized or national health technology assessment, creating a disciplined environment for clinical evidence and reimbursement decisions. The Middle East, especially GCC markets, benefits from healthcare investment, insurance expansion, and high obesity prevalence, whereas Africa remains underdiagnosed, with access tied to affordable generics, diagnostic capacity, trained clinicians, and urban healthcare expansion.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets show uneven but rising demand, shaped by retail pharmacy access, hospital-based specialist care, and expanding middle-class healthcare spending in countries with different reimbursement maturity levels. The GCC is distinguished by high metabolic disease burden, insurance expansion, and investment in tertiary care, supporting demand for both established PPIs and premium therapies where reimbursement and formulary access are available.

The European Union emphasizes regulatory rigor, pharmacovigilance, generics, and health technology assessment, making evidence quality essential for GERD therapeutics. BRICS countries combine large patient pools with strong generic competition, local manufacturing priorities, and growing diagnostic infrastructure. G7 markets lead in clinical research, regulatory oversight, and branded innovation, while NATO should be viewed primarily as a supply-chain resilience and procurement continuity lens rather than a healthcare purchasing bloc, given its diverse national reimbursement systems and separate medicine access policies.

Key Country Insights for Priority GERD Markets

The United States leads commercialization through FDA pathways, OTC-to-prescription channel breadth, broad direct-to-consumer awareness, and rapid uptake of differentiated drugs when outcomes justify coverage. Canada emphasizes evidence-based reimbursement, while Mexico and Brazil are scale markets where COFEPRIS and ANVISA oversight, generic penetration, and private-sector access shape adoption. The United Kingdom, Germany, France, Italy, and Spain are mature European markets where NICE, AMNOG, HAS, and regional procurement frameworks influence pricing, prescribing, and formulary use.

Russia prioritizes domestic supply resilience and continued access to essential generics, while China and India combine large symptomatic populations with strong generic manufacturing, expanding gastroenterology capacity, and increasing use of endoscopy in urban centers. Japan is a benchmark for PCAB adoption, aging-related demand, and structured gastroenterology care. Australia's TGA and PBS frameworks support evidence-led access, and South Korea's NHIS environment, advanced endoscopy capacity, and strong hospital networks support structured diagnosis, monitoring, and treatment optimization.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated evidence over incremental positioning. Clinical programs should demonstrate healing rates, sustained symptom control, nighttime relief, adherence benefits, safety, and value in patients with inadequate response to standard PPIs. Real-world evidence should be built early to support payer discussions, treatment pathway inclusion, and guideline relevance.

Commercial teams should balance branded innovation with high-volume generic realities, invest in physician and pharmacist education, and segment patients by disease severity, diagnostic confirmation, alarm features, and treatment history. Supply-chain quality, impurity surveillance, responsible OTC communication, and digital adherence tools should be integrated into lifecycle strategy to protect trust, support appropriate use, and expand access.

Research Methodology

This executive summary is grounded in a structured review of clinical guidelines, regulatory communications, peer-reviewed literature, public health datasets, healthcare policy sources, and publicly available therapeutic class information. Core references include guidance from gastroenterology societies, FDA and EMA regulatory information, national reimbursement frameworks, and epidemiology inputs from recognized public health institutions.

Insights were triangulated across therapeutic class dynamics, patient pathways, reimbursement environments, regional healthcare capacity, regulatory trends, and technology adoption signals. The methodology emphasizes verified secondary research, consistency checks across authoritative sources, and market interpretation aligned with clinical practice rather than unsupported forecasting, market sizing, or market share claims.

Conclusion

GERD therapeutics remain a resilient and clinically essential category because reflux symptoms are common, recurrent, and often require long-term management. Generic PPIs continue to anchor treatment volume, but innovation is expanding around PCABs, optimized formulations, digital monitoring, and evidence-based treatment pathways for refractory or complicated disease.

The most successful stakeholders will align clinical differentiation with payer value, regulatory quality, patient adherence, and regional access realities. As AI, real-world evidence, and precision diagnosis mature, GERD therapeutics will move toward more targeted care models that improve symptom control, safety oversight, and resource efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Gastroesophageal Reflux Disease Therapeutics Market, by Treatment Type

  • 7.1. Pharmacologic Therapies
    • 7.1.1. Proton Pump Inhibitors (PPIs)
    • 7.1.2. H2 Receptor Antagonists
    • 7.1.3. Antacid
    • 7.1.4. Mucosal Coating Agent
      • 7.1.4.1. Sucralfate & Coating Agents
      • 7.1.4.2. Alginates/Raft Formers
  • 7.2. Surgical Interventions
  • 7.3. Device-Based Therapies

8. Gastroesophageal Reflux Disease Therapeutics Market, by Dosage Form

  • 8.1. Capsule
  • 8.2. Liquid
  • 8.3. Suspension
  • 8.4. Tablet

9. Gastroesophageal Reflux Disease Therapeutics Market, by Route Of Administration

  • 9.1. Oral
  • 9.2. Injectable

10. Gastroesophageal Reflux Disease Therapeutics Market, by Medicine Type

  • 10.1. Over-The-Counter
  • 10.2. Prescription

11. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Status

  • 11.1. Branded
  • 11.2. Generic

12. Gastroesophageal Reflux Disease Therapeutics Market, by Disease Severity

  • 12.1. Mild
  • 12.2. Moderate
  • 12.3. Severe

13. Gastroesophageal Reflux Disease Therapeutics Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Gastroesophageal Reflux Disease Therapeutics Market, by End User

  • 14.1. Home Care Settings
  • 14.2. Hospitals
  • 14.3. Specialty Clinics

15. Gastroesophageal Reflux Disease Therapeutics Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Gastroesophageal Reflux Disease Therapeutics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Gastroesophageal Reflux Disease Therapeutics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. AstraZeneca plc
  • 19.2. Aurobindo Pharma Limited
  • 19.3. Bayer AG
  • 19.4. Cadila Pharmaceuticals Ltd.
  • 19.5. Camber Pharmaceuticals, Inc.
  • 19.6. Daewoong Pharmaceutical Co., Ltd.
  • 19.7. Dr. Reddy's Laboratories Limited
  • 19.8. Eisai Co., Ltd.
  • 19.9. Elite Wealth Ltd.
  • 19.10. Haleon plc
  • 19.11. HK inno.N Co., Ltd.
  • 19.12. Ironwood Pharmaceuticals, Inc.
  • 19.13. Johnson & Johnson Services, Inc.
  • 19.14. Lupin Limited
  • 19.15. Onconic Therapeutics Inc.
  • 19.16. Pfizer Inc.
  • 19.17. Phathom Pharmaceuticals, Inc.
  • 19.18. RaQualia Pharma Inc.
  • 19.19. Reckitt Benckiser Group plc
  • 19.20. Sandoz Group AG
  • 19.21. Sanofi S.A.
  • 19.22. Sebela Pharmaceuticals Inc.
  • 19.23. Sun Pharmaceutical Industries Limited
  • 19.24. Takeda Pharmaceutical Company Limited
  • 19.25. Teva Pharmaceutical Industries Ltd.
  • 19.26. The Procter & Gamble Company
  • 19.27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACOLOGIC THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOLOGIC THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOLOGIC THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROTON PUMP INHIBITORS (PPIS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROTON PUMP INHIBITORS (PPIS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROTON PUMP INHIBITORS (PPIS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL H2 RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL H2 RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL H2 RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTACID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTACID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTACID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MUCOSAL COATING AGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MUCOSAL COATING AGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MUCOSAL COATING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SUCRALFATE & COATING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SUCRALFATE & COATING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SUCRALFATE & COATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALGINATES/RAFT FORMERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ALGINATES/RAFT FORMERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALGINATES/RAFT FORMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SURGICAL INTERVENTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DEVICE-BASED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DEVICE-BASED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DEVICE-BASED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PRESCRIPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRESCRIPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PRESCRIPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MILD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MILD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MILD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MODERATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MODERATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MODERATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SEVERE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SEVERE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SEVERE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 176. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 177. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 178. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 209. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 210. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 211. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 220. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 221. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 222. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 226. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MEDICINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DRUG STATUS, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY MUCOSAL COATING AGENT, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RO